Auriant Mining AB (publ.) publishes interim report for the

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Auriant Mining AB (publ.) publishes interim report for the period January – September 2015

Highlights

·  Tardan gold production increased by 28% to 550 kg (17,671 oz), compared to 429 kg (13,779 oz) in 9 months 2014.

·  Total 9 months gold production was 556 kg (17,864 oz), 25 % less than the comparable period last year (746 kg (23,984 oz)) due to the lack of alluvial production in 2015 (9 months 2014 alluvial production – 254 kg).

·  Gold grades at Tardan were 2.50 g/t which is a significant increase compared to 9 months 2014 (1.56 g/t).

· The volume of ore mined at Tardan (367,000 tonnes) increased by 63% from 9 months 2014.

· Cash costs per ounce of gold produced decreased by 34% down to US$ 855/oz in 9 months 2015 ($1,302/oz in 9 months 2014).

·  EBITDA for the period was positive at MSEK 57.3 (US$ 6.8 m) compared to 9 months 2014 negative amount of MSEK -27.3 (US$ -4.3 m).

·  Consolidated gross profit significantly improved and was positive in 9 months 2015 at MSEK 25.7 (US$ 2.9 m) compared to a loss in 9 months 2014 of MSEK -35.9 (US$ -5.5 m).

·  Consolidated operating profit in 9 months 2015 at MSEK 3.2 (US$ 0.3 m) is on breakeven, compared to operating loss of same period of 2014 in amount of MSEK -63.6 (US$ -9.7 m).

Full report is available here

The interim report will be followed by an interactive webcast for analysts and investors with the CEO, Denis Alexandrov and CFO, Sergey Ustimenko who will be presenting Auriant Mining’s Q3 2015 results as well as hosting a Q&A session.

The event will begin at 10:00 CET (10:00 Stockholm, 12:00 Moscow, 09:00 London).

Those wishing to participate will need to pre-register for this event by clicking here

For more information, please contact:

 

Denis Alexandrov, CEO

tel: +7 495 660 22 20

e-mail: denis.alexandrov@auriant.com

 

 

Company name: Auriant Mining AB

Short name: AUR

ISIN-code: SE0001337213

 

Website: www.auriant.com Twitter: @auriantmining

 

Auriant Mining AB (AUR) is a Swedish junior mining company focused on gold exploration and production in Russia, primarily in Zabaikalye and the Republics of Khakassia and Tyva. The company has currently four assets, including two operating mines (Tardan and Solcocon) one early stage exploration asset and one development asset. The group’s mineral licenses are estimated to contain official Russian State Reserves Committee (GKZ) reserves of 829 500, 000 troy ounces (1 oz = 31.1 g) in the C1 and C2 categories and 500,000 troy ounces in NI 43-101 standard. Since January 2015 the Company is also managing 5 gold assets at Chukotka, including working mine Valunisty.

Since July 19, 2010, Auriant Mining´s shares are traded on First North Premier at the NASDAQ OMX Nordic Exchange under the short name AUR . For more information please visit www.auriant.com. Mangold Fondkommission is Certified Adviser to Auriant, for more information please call +46 8 503 015 50 or visit www.mangold.se.

Cautionary Statement: Statements and assumptions made in this report with respect to Auriant Mining AB’s (“AUR”) current plans, estimates, strategies and beliefs, and other statements that are not historical facts, are forward-looking statements about the future performance of AUR. Forward-looking statements include, but are not limited to, those using words such as "may", "might", "seeks", "expects", "anticipates", "estimates", "believes", "projects", "plans", strategy", "forecast" and similar expressions. These statements reflect management's expectations and assumptions in light of currently available information. They are subject to a number of risks and uncertainties, including, but not limited to, (i) changes in the economic, regulatory and political environments in the countries where AUR operates; (ii) changes relating to the geological information available in respect of the various projects undertaken; (iii) AUR’s continued ability to secure enough financing to carry on its operations as a going concern; (iv) the success of its potential joint ventures and alliances, if any; (v) exchange rates, particularly between the Russian rouble and the U.S. dollar. In the light of the many risks and uncertainties surrounding any gold production and exploration company at an early stage of its development, the actual results could differ materially from those presented and forecast in this report. AUR assumes no unconditional obligation to immediately update any such statements and/or forecasts

This press release shall not, directly or indirectly, be released, published or distributed in or to the United States, Australia Japan, Canada, New Zealand, Hong Kong, South Africa or other country where such action as a  whole or in part is subject to legal restrictions. Nothing in this press release should be considered as an offer to invest or otherwise trade in shares of Auriant Mining AB (publ). The proposed issue will not be directed at residents or those living in the United States, Australia, Japan, Canada, New Zealand, Hong Kong, South Africa or other country where such action would require further prospectus, other offering documentation, registration or other measures beyond those required by Swedish law. No securities will be registered under the United States Securities Act of 1933, a similar law in any state in the United States, or under any provincial law in Canada, nor under the applicable law of another country.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

FFR's OmniMind Takes Top Spot In RoboColiseum Rankings

Updated Category News Views 80

The AI Race Heats Up with FFR's Big Win Stop the presses—FFR's OmniMind AI just snagged the top spot on RoboColiseum's global rankings. Yeah, you heard right, this ain't just some run-of-the-mill news. As of November 6, they've parked themselves in pole position, beating out heavyweights like NVIDIA's GR00T N1.7 and GPT-6 Astra. That's like hitting a grand slam right...

Continue Reading
Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 242

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
MWC26 Doha: Bridging Standards for MENA's Future

Updated Category News Views 559

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 351

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 74

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 273

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Xiaomi's Smart Auto Factory Draws Global Media Praise

Updated Category News Views 25

Xiaomi Impresses Global Media in Beijing Factory Tour In the ever-changing world of NEVs (New Energy Vehicles), a tour of Xiaomi's smart auto factory in Beijing has made waves among global media folks. These scribes got an up-close look at Xiaomi's magic mix of tech and style on November 6, part of a grand media gathering. What's Under the Hood? Marcos Costa de Oliveira,...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 612

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 344

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 343

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading

Top 5 Most Recently Viewed Articles

Investors Alert: LifeMD Inc Faces Legal Investigation Risks

Updated Category News Views 167

Understanding Recent Developments for LifeMD, Inc. LifeMD, Inc. (NASDAQ: LFMD) is presently facing serious legal scrutiny following an investigation initiated by Faruqi & Faruqi, LLP. This renowned national securities law firm has stepped in to evaluate potential claims on behalf of investors. Investor Engagement Opportunities If you are among the investors who incurred...

Continue Reading
Value Stocks Poised for Growth Amid Market Shifts

Updated Category News Views 119

Value Stocks Set for Growth as Market Dynamics Change The stock market is currently experiencing a notable shift away from tech dominance. In recent months, tech stocks have faced challenges, raising questions about the potential revival of value stocks. This change in market sentiment is particularly evident in the impressive performance of the Value ETF, which has...

Continue Reading
EXEL Industries Reveals Key Share and Voting Rights Insights

Updated Category News Views 57

EXEL Industries Overview EXEL Industries is a prominent French Société Anonyme, with a robust share capital amounting to €16,969,750. The company has established a significant presence in the industry through its high standards and innovative products. Understanding Share Capital and Voting Rights On August 31, 2024, EXEL Industries provided updated insights regarding...

Continue Reading
Protective Life Corporation Strengthens Portfolio with Acquisition

Updated Category News Views 112

Protective Life Corporation Strengthens Its Portfolio In a significant development for Protective Life Corporation, the company has successfully completed the acquisition of ShelterPoint Group, Inc. Shielded under the corporate umbrella of Dai-ichi Life Holdings, Inc., Protective Life Corporation continues to solidify its position in the employee benefits industry. This...

Continue Reading
Safeguarding Your Personal Data in a Digital Health Era

Updated Category News Views 160

Understanding the Importance of Data Security in Health Tech As the holiday season approaches, consumers are excitedly purchasing various digital health tools such as fitness trackers, meditation apps, and smart scales. While these innovations can greatly enhance our wellness journey, they also raise significant concerns regarding the security of our personal data. Expert...

Continue Reading